Stock AZTR AZITRA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Azitra, Inc.

Equities

AZTR

US05479L1044

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:10:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
0.2485 USD -4.42% Intraday chart for Azitra, Inc. +13.01% -72.99%
Apr. 22 Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting CI
Mar. 15 Azitra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2023 2024 2025 2026
Capitalization 1 11.13 7.489 - -
Enterprise Value (EV) 1 11.13 7.489 7.489 7.489
P/E ratio -0.5 x -0.87 x -0.87 x -0.76 x
Yield - - - -
Capitalization / Revenue 16.2 x - 4.99 x -
EV / Revenue 16.2 x - 4.99 x -
EV / EBITDA - - - -
EV / FCF -1.51 x -0.8 x -0.73 x -0.57 x
FCF Yield -66.4% -125% -138% -175%
Price to Book - - - -
Nbr of stocks (in thousands) 12,098 28,805 - -
Reference price 2 0.9200 0.2600 0.2600 0.2600
Announcement Date 3/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - 0.686 - 1.5 -
EBITDA - - - - -
EBIT 1 - -7.616 -8.693 -13.33 -12.22
Operating Margin - -1,110.26% - -888.77% -
Earnings before Tax (EBT) - - - - -
Net income 1 -10.68 -12.64 -8.693 -9.563 -12.22
Net margin - -1,842.44% - -637.53% -
EPS 2 -90.47 -1.830 -0.3000 -0.3000 -0.3400
Free Cash Flow 1 - -7.389 -9.371 -10.31 -13.14
FCF margin - -1,077.1% - -687.27% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 2/21/23 3/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q3 2023 Q4
Net sales 1 - 0.09
EBITDA - -
EBIT 1 - -2.58
Operating Margin - -2,866.71%
Earnings before Tax (EBT) - -
Net income 1 -1.943 -2.454
Net margin - -2,726.43%
EPS -0.1600 -
Dividend per Share - -
Announcement Date 11/14/23 3/15/24
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -7.39 -9.37 -10.3 -13.1
ROE (net income / shareholders' equity) - - - - -
ROA (Net income/ Total Assets) - - - - -
Assets 1 - - - - -
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex - 0.03 - - -
Capex / Sales - 3.87% - - -
Announcement Date 2/21/23 3/15/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.26 USD
Average target price
3.5 USD
Spread / Average Target
+1,246.15%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AZITRA, INC. Stock Azitra, Inc.
-72.99% 7.49M
MODERNA, INC. Stock Moderna, Inc.
+23.37% 46.71B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.94% 41.52B
CELLTRION, INC. Stock Celltrion, Inc.
-5.86% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.29% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.92% 19.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+3.20% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.67% 12.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.23% 11.98B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AZTR Stock
  4. Financials Azitra, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW